Perimeter Medical Imaging AI Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update Conference Call/Webcast Today at 5 pm ET
Perimeter Medical Imaging AI (PYNKF) reported its Q4 and full-year 2024 financial results, highlighting significant commercial growth. The company achieved nine new S-Series OCT system placements in 2024, up from three in 2023, with Q4-2024 revenues increasing 303% year-over-year to $293,000.
The company's pivotal study for its next-generation B-Series OCT with ImgAssist AI 2.0 met its primary endpoint, demonstrating statistically significant reduction in patients with residual cancer during breast-conserving surgeries. Perimeter recently submitted a Premarket Approval (PMA) application to the FDA for this technology.
Financial highlights for FY2024 include:
- Revenue of $846,000, up 110% from 2023
- Operating expenses of $19.4 million
- Net loss of $13.4 million ($0.19 per share)
- Cash position of $6.2 million as of December 31, 2024
- Additional $2.0 million CPRIT grant receivable
Perimeter Medical Imaging AI (PYNKF) ha riportato i risultati finanziari del quarto trimestre e dell'intero anno 2024, evidenziando una significativa crescita commerciale. L'azienda ha raggiunto nove nuove installazioni di sistemi OCT della serie S nel 2024, rispetto alle tre del 2023, con un aumento del 303% dei ricavi del Q4-2024, che hanno raggiunto i 293.000 dollari.
Lo studio fondamentale dell'azienda per la sua prossima generazione di B-Series OCT con ImgAssist AI 2.0 ha raggiunto il suo obiettivo primario, dimostrando una riduzione statisticamente significativa nei pazienti con cancro residuo durante le chirurgie di conservazione del seno. Perimeter ha recentemente presentato una domanda di approvazione pre-commerciale (PMA) alla FDA per questa tecnologia.
I punti salienti finanziari per l'anno fiscale 2024 includono:
- Ricavi di 846.000 dollari, in aumento del 110% rispetto al 2023
- Spese operative di 19,4 milioni di dollari
- Perdita netta di 13,4 milioni di dollari (0,19 dollari per azione)
- Posizione di liquidità di 6,2 milioni di dollari al 31 dicembre 2024
- Ulteriori 2,0 milioni di dollari di sovvenzioni CPRIT da ricevere
Perimeter Medical Imaging AI (PYNKF) informó sus resultados financieros del cuarto trimestre y del año completo 2024, destacando un crecimiento comercial significativo. La compañía logró nueve nuevas instalaciones de sistemas OCT de la serie S en 2024, en comparación con tres en 2023, con ingresos en el Q4-2024 que aumentaron un 303% interanual, alcanzando los 293,000 dólares.
El estudio clave de la compañía para su próxima generación de B-Series OCT con ImgAssist AI 2.0 cumplió su objetivo principal, demostrando una reducción estadísticamente significativa en pacientes con cáncer residual durante las cirugías de conservación de senos. Perimeter recientemente presentó una solicitud de aprobación previa al mercado (PMA) a la FDA para esta tecnología.
Los aspectos financieros destacados para el año fiscal 2024 incluyen:
- Ingresos de 846,000 dólares, un aumento del 110% con respecto a 2023
- Gastos operativos de 19.4 millones de dólares
- Pérdida neta de 13.4 millones de dólares (0.19 dólares por acción)
- Posición de efectivo de 6.2 millones de dólares al 31 de diciembre de 2024
- Subvención adicional de 2.0 millones de dólares de CPRIT por cobrar
Perimeter Medical Imaging AI (PYNKF)는 2024년 4분기 및 연간 재무 결과를 보고하며 상당한 상업적 성장을 강조했습니다. 이 회사는 2024년에 S시리즈 OCT 시스템 9개 신규 설치를 달성했으며, 이는 2023년의 3개에서 증가한 수치로, 2024년 4분기 수익은 전년 대비 303% 증가하여 293,000달러에 달했습니다.
회사의 차세대 B-Series OCT with ImgAssist AI 2.0에 대한 주요 연구는 주요 목표를 달성하여 유방 보존 수술 중 잔여 암 환자에서 통계적으로 유의미한 감소를 보여주었습니다. Perimeter는 이 기술에 대한 사전 시장 승인(PMA) 신청서를 FDA에 제출했습니다.
2024 회계연도의 재무 하이라이트는 다음과 같습니다:
- 수익 846,000달러, 2023년 대비 110% 증가
- 운영 비용 1,940만 달러
- 순손실 1,340만 달러 (주당 0.19달러)
- 2024년 12월 31일 기준 현금 보유액 620만 달러
- 추가적인 200만 달러 CPRIT 보조금 수취 예정
Perimeter Medical Imaging AI (PYNKF) a publié ses résultats financiers du quatrième trimestre et de l'année 2024, mettant en avant une croissance commerciale significative. L'entreprise a réalisé neuf nouvelles installations de systèmes OCT de la série S en 2024, contre trois en 2023, avec des revenus au T4-2024 augmentant de 303 % d'une année sur l'autre pour atteindre 293 000 dollars.
L'étude clé de l'entreprise pour sa prochaine génération de B-Series OCT avec ImgAssist AI 2.0 a atteint son objectif principal, démontrant une réduction statistiquement significative chez les patients ayant un cancer résiduel lors des interventions de conservation du sein. Perimeter a récemment soumis une demande d'approbation préalable à la commercialisation (PMA) à la FDA pour cette technologie.
Les points saillants financiers pour l'exercice 2024 comprennent :
- Revenus de 846 000 dollars, en hausse de 110 % par rapport à 2023
- Dépenses d'exploitation de 19,4 millions de dollars
- Perte nette de 13,4 millions de dollars (0,19 dollar par action)
- Position de trésorerie de 6,2 millions de dollars au 31 décembre 2024
- Subvention CPRIT supplémentaire de 2,0 millions de dollars à recevoir
Perimeter Medical Imaging AI (PYNKF) hat seine Finanzzahlen für das vierte Quartal und das Gesamtjahr 2024 veröffentlicht und dabei ein signifikantes kommerzielles Wachstum hervorgehoben. Das Unternehmen erzielte neun neue Installationen von S-Serie OCT-Systemen im Jahr 2024, ein Anstieg von drei im Jahr 2023, wobei die Einnahmen im Q4-2024 im Jahresvergleich um 303% auf 293.000 Dollar stiegen.
Die entscheidende Studie des Unternehmens für die nächste Generation des B-Series OCT mit ImgAssist AI 2.0 erreichte ihr primäres Ziel und zeigte eine statistisch signifikante Reduktion bei Patienten mit verbleibendem Krebs während der brusterhaltenden Operationen. Perimeter hat kürzlich einen Antrag auf Marktzulassung (PMA) bei der FDA für diese Technologie eingereicht.
Finanzielle Höhepunkte für das Geschäftsjahr 2024 umfassen:
- Einnahmen von 846.000 Dollar, ein Anstieg von 110% im Vergleich zu 2023
- Betriebsausgaben von 19,4 Millionen Dollar
- Nettoverlust von 13,4 Millionen Dollar (0,19 Dollar pro Aktie)
- Liquiditätsposition von 6,2 Millionen Dollar zum 31. Dezember 2024
- Zusätzliche 2,0 Millionen Dollar CPRIT-Zuschussforderung
- 303% revenue growth in Q4 2024 vs Q4 2023
- 110% increase in full-year revenue to $846,000
- Successful pivotal trial results for B-Series OCT with ImgAssist AI 2.0
- 200% increase in system placements (9 vs 3) year-over-year
- 35% improvement in Q4 net loss compared to previous year
- FDA PMA application submitted for B-Series OCT
- Operating expenses increased 16% to $19.4M in 2024
- Net loss of $13.4M for full-year 2024
- cash position of $6.2M as of December 31, 2024
Business Highlights
- The Company continues to gain positive commercial market traction with its first
U.S. Food and Drug Administration ("FDA")-cleared product, Perimeter S-Series OCT. In 2024, Perimeter achieved nine (9) new S-Series OCT system placements, compared to three (3) in 2023, and Q4-2024 revenues grew303% over Q4-2023. In addition, the Company is advancing the development of its next-generation Perimeter B-Series OCT system, which combines proprietary AI technology with OCT, toward potential commercialization. - In November 2024, Perimeter reported topline results from the pivotal study designed to support its Premarket Approval ("PMA") application to the FDA for B-Series OCT with ImgAssist AI 2.0 ("Perimeter B-Series") for use during breast-conserving surgeries ("BCS") in
the United States . The pivotal trial met its primary endpoint, achieving a statistically significant (p-value = 0.0050) reduction in patients with residual cancer during surgery. These results demonstrated super-superiority (lower bound of confidence interval for treatment effect greater than a predetermined minimal clinically meaningful difference) of the Perimeter B-Series' ability to aid surgeons in achieving clear surgical margins during surgery, potentially lowering the need for reoperation. - In February 2025, Perimeter announced CHRISTUS St. Vincent is the first hospital in
New Mexico to use the Company's S-Series OCT technology to visualize tissue margins in the operating room. CHRISTUS St. Vincent offers the only Commission on Cancer (CoC) accredited breast cancer program in northernNew Mexico . - Perimeter also announced that its common shares began trading on the OTCQX® Best Market under the symbol "PYNKF", effective with the open of business on February 27, 2025.
- In March 2025, Perimeter announced that detailed results from the pivotal trial evaluating the use of Perimeter B-Series during BCS will be presented during the scientific session of the 26th Annual Meeting of the American Society of Breast Surgeons (ASBrS) taking place in
Las Vegas, NV , April 30-May 4, 2025. The Company also plans to submit the detailed results for publication in one or more peer-reviewed journals. - Also in March 2025, Perimeter announced further commercial expansion, with Covenant Health Fort Sanders Regional becoming the first hospital in the state of
Tennessee to use the Company's S-Series OCT technology to visualize tissue margins in the operating room. - Last week, Perimeter announced the submission of a PMA application to the FDA for the Company's Perimeter B-Series for use during BCS in
the United States . The FDA PMA submission is a major milestone – Perimeter's first regulatory approval application for its AI-enabled wide-field OCT technology, as well as for a specific indication label.
"While we continue to make steady commercial progress with our current S-Series OCT system, in many respects we are now just approaching the starting line with the release of positive topline pivotal trial results and filing of the FDA PMA application for our next-generation AI-enabled B-Series product," commented Adrian Mendes, Perimeter's Chief Executive Officer. "We are incredibly energized by the compelling growth opportunity we see ahead, and look forward to updating investors as we progress."
Summary Third Quarter 2024 Financial Results
Perimeter reported fourth quarter 2024 revenues of approximately
Operating expenses for the three months ended December 31, 2024 were approximately
Fourth quarter 2024 net loss was approximately
Summary Full Year 2024 Financial Results
For the year ended December 31, 2024, the Company recorded revenue of approximately
Perimeter's full year 2024 operating expenses were approximately
Full year 2024 net loss was approximately
Cash used in operating activities in the 12 months ended December 31, 2024, was approximately
As of December 31, 2024, cash was approximately
For detailed financial results, please refer to Perimeter's filings on SEDAR+ and the Company's website.
Conference Call
The Company will host a conference call and live audio webcast today at 5:00 pm Eastern Time to discuss its second quarter 2024 results and provide a corporate update. To participate in the call, please dial 1-800-717-1738 or 1-646-307-1865. The conference call will also be broadcast live online through a listen-only webcast, which will be posted on the Investors section of the Company's website and archived for approximately 90 days.
About Perimeter Medical Imaging AI, Inc.
Based in
Perimeter B-Series OCT is limited by
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. In this news release, words such as "may," "would," "could," "will," "likely," "believe," "expect," "anticipate," "intend," "plan," "estimate," and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking information may relate to management's future outlook and anticipated events or results and may include statements or information regarding the future financial position, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter. Without limitation, information regarding the potential benefits of Perimeter S-Series OCT and Perimeter B-Series OCT, the expected benefits of Perimeter's updated version of its ImgAssist AI, and Perimeter's expectations regarding the outcomes of the clinical trial and future submission to the FDA are forward-looking information. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, any particular result will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management's good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions, and other unpredictable factors, many of which are beyond Perimeter's control. Such forward-looking statements reflect Perimeter's current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter's financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market, and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described in Perimeter's Management Discussion and Analysis for the year ended December 31, 2023, which is available on Perimeter's SEDAR+ profile at https://www.sedarplus.ca, and could cause actual events or results to differ materially from those projected in any forward-looking statements. Perimeter does not intend, nor does Perimeter undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events, or circumstances or otherwise, except if required by applicable laws.
CONTACTS:
Stephen Kilmer
Investor Relations
Direct: 647-872-4849
Email: skilmer@perimetermed.com
Adrian Mendes
Chief Executive Officer
Toll-free: 888-988-7465 (PINK)
Email: investors@perimetermed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/perimeter-medical-imaging-ai-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-corporate-update-conference-callwebcast-today-at-5-pm-et-302412508.html
SOURCE Perimeter Medical Imaging AI Inc.